single15MG
Trizepatide
15MG Protocol
Trizepatide 15MG
Injection Freq.
Inject once weekly
Cycle Sched.
Weekly subcutaneous injection on the same day each week for 12–16+ weeks
Reconstitution
2.0 mL BAC water
Significant HbA1c reductions reported in type 2 diabetes trials
Substantial body-weight loss reported in clinical trials
Improvements in lipid profile and blood pressure reported in some studies
Once-weekly dosing convenience
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2.5 mg | 33 |
| 2 | Weeks 5–8 | 5 mg | 67 |
| 3 | Weeks 9–12 | 7.5 mg | 100 |
| 4 | Weeks 13–16 | 10 mg | 67 |
Inject once weekly
Weekly subcutaneous injection on the same day each week for 12–16+ weeks
Trizepatide (tirzepatide) is described as a dual incretin receptor agonist that activates both GLP-1 and GIP receptors. The protocol explains that this dual mechanism increases glucose-dependent insulin secretion when glucose is present, suppresses glucagon output, slows gastric emptying, and promotes satiety through central appetite regulation. A key point emphasized is that the added GIP activity may amplify metabolic outcomes beyond GLP-1 agonism alone, which is presented as a reason trials have shown particularly strong weight-loss results. The page also highlights pharmacokinetics: an approximately 5-day half-life supports once-weekly administration with steady exposure. Mechanistically, the overall effect is improved glycemic control paired with reduced caloric intake and, over time, meaningful body-weight reduction—provided dosing is titrated gradually to improve tolerability.
Nausea
Diarrhea
Vomiting
Constipation
Mild injection-site reactions (redness/irritation)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)